PARIS – Vygon SA, of Ecouen, France, has acquired Advanced Perfusion Diagnostics SA (APD), a startup based in Lyon, France, that has developed Ikorus, a device that detects changes in visceral microvascular blood flow in the most critically ill hospital patients. Vygon did not disclose the financial details behind the agreement.
HONG KONG – Yokneam, Israel-based Serenno Medical Ltd. has unveiled a device for automatic monitoring and detection of kidney damage in patients. Known as Sentinel, the device is a continuous urine output (UO) monitor that measures urine flow rate and volume in real time.
Current Health Ltd., of Edinburgh, Scotland, scooped up $11.5 million in a series A financing that was led by MMC Ventures. The funds are earmarked to scale up Current Health’s patient management platform, with the aim of preventing global illness in 1 million patients by 2021. Legal & General Group plc, a London-based financial services company, was the largest investor in the round and represents Current Health’s first corporate investor.
PARIS – Grapheal SAS, of Grenoble, France, is developing a new generation of dressings integrating an embedded electronic biosensor. The Grapheal device consists of monolayer graphene on a polymer layer 0.3 nanometers thick. “This noninvasive embedded device collects data from the wound. The wireless e-health wound monitoring system, or smart patch, remotely reports the status of chronic wounds to the care team,” Vincent Bouchiat, co-founder and CEO at Grapheal, told BioWorld MedTech.
HONG KONG – In vitro diagnostic company Cube Bio Co. Ltd., of Seoul, South Korea, has inked an agreement worth KRW3 trillion (US$2.5 billion) with Moscow-based Standart-Biotest LLC to export its cancer self-diagnostic kits for five years to Russia and the Commonwealth of Independent States (CIS).
San Diego-based Exagen Diagnostics Inc. has a somewhat unique business model. It's aiming to both improve diagnostics and monitoring for autoimmune patients, but also to partner with biopharmas to promote better testing – and even to market related therapeutics to autoimmune specialists.
Baxter International Inc. has struck a definitive agreement to acquire Cheetah Medical Inc., a provider of noninvasive hemodynamic monitoring technologies. The Deerfield, Ill.-based company agreed to pay $190 million up front in cash, with the potential for an additional $40 million based on clinical and commercial milestones.
Getting on top of the persistent HIV epidemic requires getting ahead of new cases, but only about 7% of at-risk patients have been advised of a prophylactic drug regime approved by the FDA seven years ago. Two new studies appearing in The Lancet HIV suggest that an algorithm that uses electronic health record (EHR) data can help physicians identify their at-risk patients who are good candidates for pre-exposure prophylaxis (PrEP), thus improving the odds that modern medicine might finally put an end to the scourge of acquired immunodeficiency syndrome.
Monitoring the electrical activity within and between cells on a large scale in a living animal may seem like a task that's next to impossible. But that's precisely what researchers at Cambridge, Mass.-based Harvard University aim to do with the next iteration of nanoscale sensors in the shape of wires.
RSS
